Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

ENO1 (Enolase 1, (alpha))

Written2009-08Bogusz Trojanowicz, Cuong Hoang-Vu, Carsten Sekulla
AG Experimentelle, Chirurgische Onkologie, Universitatsklinik und Poliklinik fur Allgemein-, Viszeral- und Gefasschirurgie, Martin-Luther Universitat, Magdeburger Strasse 18, 06097 Halle/S, Germany (BT, CHV, CS); AG Experimentelle, Chirurgische Onkologie, Universitatsklinik und Poliklinik fur Kinderchirurgie, Martin-Luther Universitat, Magdeburger Strasse 18, 06097 Halle/S, Germany (BT)

(Note : for Links provided by Atlas : click)

Identity

Alias_namesENO1L1
MPB1
enolase 1
Alias_symbol (synonym)PPH
MBP-1
Other aliasEC 4.2.1.11
MBPB1
MPB-1
NNE
tau-crystallin
HGNC (Hugo) ENO1
LocusID (NCBI) 2023
Atlas_Id 40453
Location 1p36.23  [Link to chromosome band 1p36]
Location_base_pair Starts at 8921059 and ends at 8931635 bp from pter ( according to hg19-Feb_2009)  [Mapping ENO1.png]
Fusion genes
(updated 2016)
AKNA (9q32) / ENO1 (1p36.23)ARHGDIB (12p12.3) / ENO1 (1p36.23)CCDC58 (3q21.1) / ENO1 (1p36.23)
ENO1 (1p36.23) / APP (21q21.3)ENO1 (1p36.23) / CCT7 (2p13.2)ENO1 (1p36.23) / COL4A2 (13q34)
ENO1 (1p36.23) / ENO1 (1p36.23)ENO1 (1p36.23) / MAPRE1 (20q11.21)ENO1 (1p36.23) / MCUR1 (6p23)
ENO1 (1p36.23) / RPA1 (17p13.3)ENO1 (1p36.23) / UBE4A (11q23.3)ESYT2 (7q36.3) / ENO1 (1p36.23)
EXOSC6 (16q22.1) / ENO1 (1p36.23)ICAM2 (17q23.3) / ENO1 (1p36.23)IFI16 (1q23.1) / ENO1 (1p36.23)
IQCG (3q29) / ENO1 (1p36.23)LGMN (14q32.12) / ENO1 (1p36.23)LOC100507412 (-) / ENO1 (1p36.23)
SAAL1 (11p15.1) / ENO1 (1p36.23)SPTBN1 (2p16.2) / ENO1 (1p36.23)

DNA/RNA

Note Alpha-Enolase (ENO1, alpha enolase, non-neuronal enolase) is one of the three enolase enzymes, expressed in a wide variety of tissues. The other two enolase genes, ENO2 and ENO3, encode gamma (neuron-specific) and beta (muscle-specific) enolase, respectively. The active enolase enzymes exist as homodimers of non-covalently bound subunits. Each alpha, beta or gamma subunit is encoded by separate genes. The genomic organisation of ENO1 gene is identical with that of human gamma-enolase gene. All the coding exons have exactly the same length and introns occur at analogous positions.
 
  Structure of ENO1 mRNA ; note that nucleotides number (nt), exon positions (1-12) and two translation initiation sites (ATG) are labelled.
Description The ENO1 gene consists of 12 exons distributed over 17718 bp of genomic DNA. Single alpha-enolase transcript contains two translation initiation positions and encodes two structurally and functionally distinct proteins, alpha-enolase enzyme and MYC promotor-binding protein (MBP-1).
Transcription Transcription start sites of ENO1 gene are heterogeneous and spread over 38-bp region located at 116 bp upstream from the initiation codon ATG. These multiple start sites of transcription in ENO1 gene are consistent with lack of a canonical TATA box, usually found at the position 19-27 bp upstream of the cap sites. It is worth to notice that promoter of ENO1 gene contains two perfect Myc-Max binding motifs CACGTC. Other regulatory sites found in the 5'-flanking region of ENO1 gene include AP1 (T[T/G]AGTCA), AP2 (CCCCAGGC), AP3 (GGGTGTGGAAAG), AP4 (CAGCTGTGG), AP5 (CTGTGGAATG), ATF/CREB ([T/G][A/T]CGTCA), C2 (CATGTG), CTF/NF1 (TGGCTNNNAGCCAA), E2AE-C beta (TGGGAATT), E2F (TTTCGCGC), E4TF1 (GGAAGTG), EF-C (GTTGCNNGGCAAC), MLTF/USF (GGTCACGTGGCC), Ig octamer (ATTTGCAT), PEA2 (GACCGCA), SP1 (GGGCGG), CACCC (may function as CAAT boxes) and viral core (GTGG[A/T][A/T][A/T]G).
Pseudogene A pseudogene has been identified that is located on the other arm of the same chromosome (provided by RefSeq).

Protein

 
  Structure of ENO1/MBP-1 protein; N and C termini, and amino acid (aa) positions are labelled.
Description Alpha-Enolase (ENO1), like two other isoenzymes (gamma-ENO2 and beta-ENO3), is made up of two identical (homodimer), non-covalently bound alpha alpha subunits; alpha-Enolase is resolved during 1D-PAGE as a protein with molecular weight of about 48kDa (434 amino acids). It was demonstrated that in brain and neurons, specific enolases may exist as heterodimers, such as alpha alpha, alpha beta, beta beta, alpha gamma and gamma gamma. The proportions of isoenzymes alpha alpha, alpha beta and beta beta change in heart and muscle during embryonic development. In both mentioned tissues, isoform alpha was found predominantly in fetus. In adult heart this subunit is replaced by types alpha beta and beta beta, and in muscle by type beta beta. In human adult brain tissues, apha-type and gamma-type enolase subunits are present at similar concentrations.
Two identical subunits of alpha-Enolase facilitate each other in an antiparallel fashion. Each subunit is made up of two distinct domains: N-terminal domain, consisting of three beta-sheets and four alpha-helices (beta3 alpha4 topology), and larger C-terminal domain with eightfold alpha beta barrel structure with beta beta alpha alpha(beta alpha)6 topology. This domain contains two beta-sheets at the beginning, followed by two alpha-helices and ends with a barrel made up of alternating beta-sheets and alpha-helices (beta - sheets are surrounded by the alpha - helices). The N-terminal of one subunit contacts the C-terminal of the second in such way, that glutamic acid at position 20 (Glu20) forms an ionic pair with arginine at position 414 (Arg414).
Alternatively translated product of ENO1 gene, called MBP-1 (MYC promotor-binding protein), is expressed as a 37kDa (338 amino acids) protein and does not posses the enolase enzyme activity.
Expression Apha-Enolase is widely expressed in variety of tissues including liver, brain, kidney, spleen, adipose as well as thyroid. In comparison with gamma-type subunit found only in neurons, type alpha subunit was also detected in astrocytes, ependymal cells, capillary endothelial cells, Schwann cells and arachnoidal endothelial cells.
Localisation Alpha-Enolase is most abundantly found in cytoplasm and also on the cell surface. MBP-1 is localised in the nucleus.
Function Enolase enzymes (2-phospho-D-glycerate hydrolases) catalyse the dehydration of 2-phospho-D-glycerate (PGA) to phosphoenolopyruvate (PEP) in Emden Mayerhoff-Parnas glycolytic pathway (catabolic direction). In anabolic pathway (reverse reaction) during gluconeogenesis, the same enzyme catalyses hydration of PEP to PGA (hence it is called phosphopyruvate hydratase). Metal ions are cofactors impairing the increase of enolase activity; hence it is also called metal-activated metalloenzyme. Magnesium is a natural cofactor causing the highest activity. The relative activation strength profile of metal ions involved in the enzyme activity appears in the following rank of order Mg2+ > Zn2+ > Mn2+ > Fe(II)2+ > Cd2+ > Co2+, Ni2+, Sm3+, Tb3+ and most other divalent metal ions. In reaction catalyzed by enolases, the alpha-proton from a carbon adjacent to a carboxylate group of PGA, is abstracted, and PGA is conversed to enolate anion intermediate. This intermediate is further processed in a variety of chemical reactions, including racemization, cycloisomerization and beta-elimination of either water or ammonia.
The smaller product of ENO1 gene, MBP-1, is known as c-myc binding protein and negative regulator of its expression. C-myc is a DNA-binding phosphoprotein and a key regulator of cell behaviour. Many of c-myc targeting pathways are deregulated in cancer cells and contribute to its enhanced expression. There are four c-myc promoters, designated as P0, P1, P2 and P3, although in normal and cancer cells most mRNAs initiate at the P2 promoter. MBP-1 binds in a region +123 to +153 relative to the c-myc P2 promoter and probably by preventing the formation of a transcription initiation complex, decrease c-myc promoter activity. Hence MBP-1 is considered as tumor suppressor.
ENO1 protein was also found as a structural component of the eye lenses and was designated as tau-crystalin. ENO1 enzyme and tau-crystalin are the products of the same gene. Tau-crystalins are the major components of vertebrate lens. These proteins are mainly found in monomeric form with a low enzymatic activity, while the active ENO1 enzyme exists as a dimer. Irrespective of ENO1 enzyme activity, its significant presence in eye lens (23% of the total protein of the lens) clearly indicate ENO1 structural role in lens and cataracts.
In hypoxic conditions elevated ENO1 levels may provide protection to the cells by increasing anaerobic metabolism.
 
  Reaction catalyzed by Enolase.
Homology Currently, amino acid sequences of more than 50 enolase enzymes are known. The five residues that participate in catalytic activity of this enzyme are highly conserved throughout evolution. Studies in vitro revealed that mutant enolase enzymes that differs at either positions Glu168, Glu211, Lys345, Lys396 or His159, demonstrated dramatically decreased activity level. An integral and conserved part of enolases are two Mg2+ ions that participate in conformational changes of the active site of enolase and enable binding of a substrate or its analogues.

Mutations

Note The ENO1 gene maps to a region of chromosome 1 (1p35-p36) reported to be often deleted in several human malignancies, including neuroblastoma, melanoma, pheochromocytoma, breast, liver and colon cancer. However screening of neuroblastomas at different stages, failed to detect any mutations in ENO1 gene.
Amplification of ENO1 gene, as well as PAX7 (region 1pter-p33) was found to be a common phenomenon in squamous cell lung carcinoma.

Implicated in

Note
  
Entity Non-Small Cell Lung Cancer (NSCLC)
Note Higher expression of ENO1 was demonstrated in NSCLC tissues as compared with normal lung tissues. Detection and expression level of ENO1 in primary tumors were the key factors contributing to overall patient's survival rates. Relatively higher ENO1 levels in tumors correlated with poorer survival outcomes and tumor recurrence.
Other report suggests that ENO1 down-regulation in patients with NSCLC, predicts more aggressive biological behaviour. The patients whose tumors showed decreased ENO1 production had significantly poorer overall survival when compared with those without ENO1 reduction.
Also in proteomic studies, ENO1 was one of the secreted proteins demonstrated to be overexpressed by NSCLC cell line A549 as compared to controls.
Studies in vitro performed on NSCLC cell line H1299, revealed that MBP-1 overexpression correlated with decreased cell proliferation as compared with corresponding controls. Investigations in vivo demonstrated tumor suppressive properties of MBP-1. In mice with induced tumors (injection of H1299) administration of adenovirus MBP-1 construct significantly reduced tumor growth and prolonged animal survival rates.
  
  
Entity Small Cell Lung Cancer
Note There is some evidence concerning the role of anti-alpha-enolase antibodies in cancer associated retinopathy with SCLC. In serum obtained from patient with a sudden loss of vision, the only detectable antibodies were those against a 35-kDa anti-retinal protein. Surgical treatment performed after 1 week and 1 month, led to changes in the antibody response from antibodies against p35kDa to alpha-enolase after tumor resection. SCLC may express high levels of alpha-enolase and anti-alpha-enolase antibodies are typically detected after diagnosis of cancer.
  
  
Entity Thyroid carcinoma
Note In thyroid oncocytomas, which represent a subgroup of follicular thyroid carcinoma (FTC), the up-regulation of ENO1, GPI (glucose phosphate isomerase) and GAPDH (glyceraldehydes-3-phosphate dehydrogenase) was identified as metabolic signature of thyroid carcinoma.
Important role of ENO1 in progression of thyroid carcinoma was also demonstrated for cell lines established from FTC. Pre-treatment of these cell lines with retinoic acid (RA) used in therapy and chemoprevention of solid cancers, led to decrease in ENO1 and MBP-1 expression, accompanied by reduced invasiveness of the thyroid carcinoma cells. Similar effects were also observed after silencing of common the MYC promoter-binding domain found in ENO1 and MBP-1. Both, RA-mediated and siRNA induced reduction of ENO1/MBP-1 resulted in down-regulation of c-Myc oncoprotein. It seems that in FTC the bi-functional role of ENO1 gene products is diminished and ENO1 posses the enzymatic activity only. It is worth to notice that ENO1 promoter contains two MYC binding sites (CACGTG). C-Myc over-expression and interaction with these sites may result in increased ENO1 expression and/or energy production.
In well differentiated medullary thyroid carcinomas MTC the relatively high amount of alpha beta and gamma gamma enolase isoenzymes was observed, indicating presumed neuroectodermal origin of these tumors. In highly undifferentiated and anaplastic MTCs, the majority of enzyme was represented as alpha alpha-enolase while alpha gamma-enolase was only weakly detectable.
  
  
Entity Hepatocellular carcinoma (HCC)
Note In proteomic studies performed on HCC cell lines and tissues, ENO1 was identified as a protein that showed stronger expression in tumor tissues when comparing to nontumorous samples. Additionally, expression of ENO1 increased with tumor dedifferentiation status. Significantly higher ENO1 expression was found in poorly differentiated HCC than in well differentiated HCC. Moreover, expression of ENO1 positively correlated with tumor size and venous invasion. Also reduction of ENO1 by specific siRNAs decreased the proliferation rates of HCC cell lines and prolonged the G2/M phase of the cell cycle.
Investigations of MBP-1 revealed its significant reduction in cirrhosis and even more diminished expression in HCC. This reduction was surprisingly accompanied by decrease in c-myc expression.
  
  
Entity Breast carcinoma
Note Increased expression of ENO1 was found in HER-2/neu positive breast tumors and cell lines when compared with corresponding controls. HER-2/neu is the receptor tyrosine kinase found to be overexpressed in up to 30% of breast cancers and is associated with increased metastasis rate and poor prognosis.
Introduction of MBP-1 gene into human breast carcinoma cells MDA-MB-231 and MCF-7 reduced their ability to penetrate basement membrane matrix and suppressed tumor formation in athymic nude mice. It is worth to notice that MCF-7 cell line is estrogen receptor positive and estrogen dependent for tumorigenicity.
It was demonstrated that translation of ENO1 mRNA in MCF-7 cell line is glucose concentration-dependent. Low glucose concentrations increased the level of MBP-1 protein accompanied by reduced proliferation rates. The levels of ENO1 mRNA remained unaffected. This suggests that effects induced by low glucose concentrations are mediated by preferential translation of MBP-1 (using the down-stream ATG codon). In contrast, physiologic or high glucose concentrations correlated with reduced levels of MBP-1 protein and markedly induced growth of the cells. Interestingly the low glucose group exhibited a dramatic increase in c-Myc expression, not observed in physiologic or high glucose conditions. As demonstrated for follicular thyroid carcinoma cells, also in this case c-Myc might directly transactivate ENO1 promoter, resulting in an increase in glucose uptake and elevated proliferation rates.
  
  
Entity Prostate cancer
Note Investigations performed on human prostate cancer cells PC3, revealed that tumor suppressive function of MBP-1 is diminished. Reduction of endogenous MBP-1 by employing specific siRNAs resulted in decreased proliferation rates accompanied by inhibition of cyclin A1 and cyclin B1 expression. Additionally, the cell size increased after depletion of MBP-1. Introduction of exogenous MBP-1 restored cyclins expression, leading to dose-dependent increase in cyclin A1 and B1 levels.
  
  
Entity Brain tumors
Note Generally, the increased levels and activity of alpha alpha-enolase correlate with brain tumorigenicity. In astrocytomas with different degrees of malignancy, oligodendrogliomas, meningiomas and ependymomas, alpha alpha-enolase was more abundant than in normal brain tissues. Among astrocytic tumors, glioblastomas revealed the highest proportion of alpha alpha-enolase as compared with control tissues.
Introduction of full length, exogenous ENO1 sequence into 1p-deleted or other neuroblastoma cell lines, led to reduction of cell growth. This suggests that in this cell lines ENO1 is preferentially translated as MBP-1 and probably does not posses the enolase enzyme activity.
  
  
Entity Multiple myeloma (plasma cell myeloma, Kahler's disease)
Note It was demonstrated, that interleukin 6 (IL-6) is implicated in the in vivo proliferation of malignant plasma cells in multiple myeloma. Studies in vitro revealed that myeloma cell line U266 treated with IL-6, responded with increased levels of MBP-1 and XBP-1 (X-box binding protein).
  
  
Entity Acute lung inflammation (pneumonia)
Note Increased ENO1 cell-surface expression on peripheral blood monocytes (PBMs) and strong ENO1 production in mononuclear cells in the alveolar space were demonstrated for pneumonia patients when compared with healthy volunteers. Elevated cell-surface expression of ENO1 on PBMs and on human leukemic monocyte lymphoma cell line U937, led to increased plasmin generation, enhanced monocyte migration through epithelial monolayers and promoted matrix degradation.
  
  
Entity Vasculitis
Note In sera from patients with clinically proven vaculitis, anti-neutrophil cytoplasmic antibodies (ANCA) reacted with proteins present in the granules of human neutrophils. 37.3 % of these sera contained the antibodies raised against 48kDa protein, identified further as cytoplasmic alpha-enolase. Antibodies directed against enolase protein, recognised only alpha isoform and were detected in sera giving ANCA staining pattern.
Disease Vasculitis (inflammatory destruction of blood vessels).
  
  
Entity Nephritis
Note In two independent studies antibodies raised against alpha-enolase were detected in 10/41 and 9/33 sera of patients with clinically proved SLE, respectively. 80% of patients from the first report and 66.7% from the second one, suffered from active nephritis.
Disease Nephritis (renal disease) caused by systemic lupus erythematosus (SLE, chronic autoimmune connective tissue disease that can affect any part of the body).
  
  
Entity Ulcerative colitis
Note Alpha-enolase antibodies were found in about 10% of ulcerative colitis patients.
  
  
Entity Crohn's disease
Note Alpha-enolase antibodies were found in about 18% of patients with Crohn's disease.
Disease Crohn's disease (autoimmune, inflammatory disease of the intestines that may affect any part of the gastrointestinal tract).
  
  
Entity Primary biliary cirrhosis and autoimmune hepatitis
Note Alpha-enolase antibodies were present in 28.6% of patients with primary biliary cirrhosis and in 31.6% with autoimmune hepatitis. Normal subjects revealed significantly lower levels of alpha-enolase antibodies when compared with both diseases. Note that antibodies against beta and gamma enolases were not found in any serum sample analysed.
  

Bibliography

Non-neuronal enolase is an endothelial hypoxic stress protein.
Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW.
J Biol Chem. 1995 Nov 17;270(46):27752-7.
PMID 7499243
 
Identification of an autoantibody against alpha-enolase in primary biliary cirrhosis.
Akisawa N, Maeda T, Iwasaki S, Onishi S.
J Hepatol. 1997 Apr;26(4):845-51.
PMID 9126798
 
Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors.
Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S, Franc B, Rodien P, Rohmer V, Bertucci F, Birnbaum D, Malthiery Y, Reynier P, Houlgatte R.
J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005.
PMID 14764826
 
Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes.
Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, Chen CY, Chen KC, Yang TY, Chou TY, Wang WH, Whang-Peng J, Shih NY.
Clin Cancer Res. 2006 Oct 1;12(19):5746-54.
PMID 17020980
 
Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior.
Chang YS, Wu W, Walsh G, Hong WK, Mao L.
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3641-4.
PMID 14506152
 
Anti-alpha-enolase antibodies in cancer-associated retinopathy with small cell carcinoma of the lung.
Dot C, Guigay J, Adamus G.
Am J Ophthalmol. 2005 Apr;139(4):746-7.
PMID 15808190
 
Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.
Ejeskar K, Krona C, Caren H, Zaibak F, Li L, Martinsson T, Ioannou PA.
BMC Cancer. 2005 Dec 16;5:161.
PMID 16359544
 
Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma.
Fan X, Solomon H, Schwarz K, Kew MC, Ray RB, Di Bisceglie AM.
Dig Dis Sci. 2001 Mar;46(3):563-6.
PMID 11318533
 
ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1).
Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A.
FEBS Lett. 2000 May 4;473(1):47-52.
PMID 10802057
 
Tumor-suppressive effects of MBP-1 in non-small cell lung cancer cells.
Ghosh AK, Steele R, Ryerse J, Ray RB.
Cancer Res. 2006 Dec 15;66(24):11907-12.
PMID 17178888
 
Structure of the human gene for alpha-enolase.
Giallongo A, Oliva D, Cali L, Barba G, Barbieri G, Feo S.
Eur J Biochem. 1990 Jul 5;190(3):567-73.
PMID 2373081
 
Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma.
Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, Oka M.
Int J Oncol. 2008 Oct;33(4):725-31.
PMID 18813785
 
Proteomic analysis of secreted proteins of non-small cell lung cancer.
Huang LJ, Chen SX, Luo WJ, Jiang HH, Zhang PF, Yi H.
Ai Zheng. 2006 Nov;25(11):1361-7.
PMID 17094902
 
Enolase activity and isoenzyme distribution in human brain regions and tumors.
Joseph J, Cruz-Sanchez FF, Carreras J.
J Neurochem. 1996 Jun;66(6):2484-90.
PMID 8632173
 
Biochemical characterization of the mouse muscle-specific enolase: developmental changes in electrophoretic variants and selective binding to other proteins.
Merkulova T, Lucas M, Jabet C, Lamande N, Rouzeau JD, Gros F, Lazar M, Keller A.
Biochem J. 1997 May 1;323 ( Pt 3):791-800.
PMID 9169614
 
Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis.
Moodie FD, Leaker B, Cambridge G, Totty NF, Segal AW.
Kidney Int. 1993 Mar;43(3):675-81.
PMID 8455367
 
Enolase isozymes in differentiated and undifferentiated medullary thyroid carcinomas.
Oskam R, Rijksen G, Lips CJ, Staal GE.
Cancer. 1985 Jan 15;55(2):394-9.
PMID 3965094
 
Multifunctional alpha-enolase: its role in diseases.
Pancholi V.
Cell Mol Life Sci. 2001 Jun;58(7):902-20. (REVIEW).
PMID 11497239
 
Autoantibodies specific for alpha-enolase in systemic autoimmune disorders.
Pratesi F, Moscato S, Sabbatini A, Chimenti D, Bombardieri S, Migliorini P.
J Rheumatol. 2000 Jan;27(1):109-15.
PMID 10648026
 
Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma.
Racz A, Brass N, Hofer M, Sybrecht GW, Remberger K, Meese EU.
Int J Oncol. 2000 Jul;17(1):67-73.
PMID 10853020
 
Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice.
Ray RB, Steele R, Seftor E, Hendrix M.
Cancer Res. 1995 Sep 1;55(17):3747-51.
PMID 7641187
 
c-myc promoter binding protein regulates the cellular response to an altered glucose concentration.
Sedoris KC, Thomas SD, Miller DM.
Biochemistry. 2007 Jul 24;46(29):8659-68. Epub 2007 Jun 27.
PMID 17595061
 
Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene.
Subramanian A, Miller DM.
J Biol Chem. 2000 Feb 25;275(8):5958-65.
PMID 10681589
 
Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis.
Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K.
Proteomics. 2005 Apr;5(6):1686-92.
PMID 15800975
 
Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines.
Trojanowicz B, Winkler A, Hammje K, Chen Z, Sekulla C, Glanz D, Schmutzler C, Mentrup B, Hombach-Klonisch S, Klonisch T, Finke R, Kohrle J, Dralle H, Hoang-Vu C.
J Mol Endocrinol. 2009 Mar;42(3):249-60. Epub 2008 Dec 5.
PMID 19060179
 
Report of the second international workshop on human chromosome 1 mapping 1995.
Weith A, Brodeur GM, Bruns GA, Matise TC, Mischke D, Nizetic D, Seldin MF, van Roy N, Vance J.
Cytogenet Cell Genet. 1996;72(2-3):114-44.
PMID 8978760
 
Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
Wen XY, Stewart AK, Sooknanan RR, Henderson G, Hawley TS, Reimold AM, Glimcher LH, Baumann H, Malek LT, Hawley RG.
Int J Oncol. 1999 Jul;15(1):173-8.
PMID 10375612
 
Tau-crystallin/alpha-enolase: one gene encodes both an enzyme and a lens structural protein.
Wistow GJ, Lietman T, Williams LA, Stapel SO, de Jong WW, Horwitz J, Piatigorsky J.
J Cell Biol. 1988 Dec;107(6 Pt 2):2729-36.
PMID 2462567
 
Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung.
Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, Markart P, Preissner KT.
Blood. 2009 May 28;113(22):5588-98. Epub 2009 Jan 30.
PMID 19182206
 
Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags.
Yoon SY, Kim JM, Oh JH, Jeon YJ, Lee DS, Kim JH, Choi JY, Ahn BM, Kim S, Yoo HS, Kim YS, Kim NS.
Int J Oncol. 2006 Aug;29(2):315-27.
PMID 16820872
 
Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES.
Mol Cell Proteomics. 2005 Nov;4(11):1686-96. Epub 2005 Jul 26.
PMID 16048908
 

Citation

This paper should be referenced as such :
Trojanowicz, B ; Hoang-Vu, C ; Sekulla, C
ENO1 (Enolase 1, (alpha))
Atlas Genet Cytogenet Oncol Haematol. 2010;14(7):635-640.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/ENO1ID40453ch1p36.html


External links

Nomenclature
HGNC (Hugo)ENO1   3350
Cards
AtlasENO1ID40453ch1p36
Entrez_Gene (NCBI)ENO1  2023  enolase 1
AliasesENO1L1; HEL-S-17; MPB1; NNE; 
PPH
GeneCards (Weizmann)ENO1
Ensembl hg19 (Hinxton)ENSG00000074800 [Gene_View]  chr1:8921059-8931635 [Contig_View]  ENO1 [Vega]
Ensembl hg38 (Hinxton)ENSG00000074800 [Gene_View]  chr1:8921059-8931635 [Contig_View]  ENO1 [Vega]
ICGC DataPortalENSG00000074800
TCGA cBioPortalENO1
AceView (NCBI)ENO1
Genatlas (Paris)ENO1
WikiGenes2023
SOURCE (Princeton)ENO1
Genetics Home Reference (NIH)ENO1
Genomic and cartography
GoldenPath hg19 (UCSC)ENO1  -     chr1:8921059-8931635 -  1p36.2   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)ENO1  -     1p36.2   [Description]    (hg38-Dec_2013)
EnsemblENO1 - 1p36.2 [CytoView hg19]  ENO1 - 1p36.2 [CytoView hg38]
Mapping of homologs : NCBIENO1 [Mapview hg19]  ENO1 [Mapview hg38]
OMIM172430   
Gene and transcription
Genbank (Entrez)AF035286 AK098420 AK222517 AK223192 AK298600
RefSeq transcript (Entrez)NM_001201483 NM_001428
RefSeq genomic (Entrez)NC_000001 NC_018912 NG_029470 NT_032977 NW_004929289
Consensus coding sequences : CCDS (NCBI)ENO1
Cluster EST : UnigeneHs.517145 [ NCBI ]
CGAP (NCI)Hs.517145
Alternative Splicing GalleryENSG00000074800
Gene ExpressionENO1 [ NCBI-GEO ]   ENO1 [ EBI - ARRAY_EXPRESS ]   ENO1 [ SEEK ]   ENO1 [ MEM ]
Gene Expression Viewer (FireBrowse)ENO1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)2023
GTEX Portal (Tissue expression)ENO1
Protein : pattern, domain, 3D structure
UniProt/SwissProtP06733   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP06733  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP06733
Splice isoforms : SwissVarP06733
Catalytic activity : Enzyme4.2.1.11 [ Enzyme-Expasy ]   4.2.1.114.2.1.11 [ IntEnz-EBI ]   4.2.1.11 [ BRENDA ]   4.2.1.11 [ KEGG ]   
PhosPhoSitePlusP06733
Domaine pattern : Prosite (Expaxy)ENOLASE (PS00164)   
Domains : Interpro (EBI)Enolase    Enolase_C    Enolase_C-like    Enolase_CS    Enolase_N    Enolase_N-like   
Domain families : Pfam (Sanger)Enolase_C (PF00113)    Enolase_N (PF03952)   
Domain families : Pfam (NCBI)pfam00113    pfam03952   
Conserved Domain (NCBI)ENO1
DMDM Disease mutations2023
Blocks (Seattle)ENO1
PDB (SRS)2PSN    3B97   
PDB (PDBSum)2PSN    3B97   
PDB (IMB)2PSN    3B97   
PDB (RSDB)2PSN    3B97   
Structural Biology KnowledgeBase2PSN    3B97   
SCOP (Structural Classification of Proteins)2PSN    3B97   
CATH (Classification of proteins structures)2PSN    3B97   
SuperfamilyP06733
Human Protein AtlasENSG00000074800
Peptide AtlasP06733
HPRD01400
IPIIPI00465248   IPI00759806   
Protein Interaction databases
DIP (DOE-UCLA)P06733
IntAct (EBI)P06733
FunCoupENSG00000074800
BioGRIDENO1
STRING (EMBL)ENO1
ZODIACENO1
Ontologies - Pathways
QuickGOP06733
Ontology : AmiGOphosphopyruvate hydratase complex  negative regulation of transcription from RNA polymerase II promoter  magnesium ion binding  in utero embryonic development  DNA binding  transcription factor activity, sequence-specific DNA binding  transcription corepressor activity  phosphopyruvate hydratase activity  protein binding  extracellular space  nucleus  nucleus  cytoplasm  cytosol  gluconeogenesis  transcription, DNA-templated  response to virus  membrane  extrinsic component of plasma membrane  negative regulation of cell growth  M band  myelin sheath  poly(A) RNA binding  negative regulation of transcription, DNA-templated  negative regulation of transcription, DNA-templated  protein heterodimerization activity  GTPase binding  positive regulation of binding  canonical glycolysis  extracellular exosome  
Ontology : EGO-EBIphosphopyruvate hydratase complex  negative regulation of transcription from RNA polymerase II promoter  magnesium ion binding  in utero embryonic development  DNA binding  transcription factor activity, sequence-specific DNA binding  transcription corepressor activity  phosphopyruvate hydratase activity  protein binding  extracellular space  nucleus  nucleus  cytoplasm  cytosol  gluconeogenesis  transcription, DNA-templated  response to virus  membrane  extrinsic component of plasma membrane  negative regulation of cell growth  M band  myelin sheath  poly(A) RNA binding  negative regulation of transcription, DNA-templated  negative regulation of transcription, DNA-templated  protein heterodimerization activity  GTPase binding  positive regulation of binding  canonical glycolysis  extracellular exosome  
Pathways : KEGGGlycolysis / Gluconeogenesis    RNA degradation    HIF-1 signaling pathway   
REACTOMEP06733 [protein]
REACTOME Pathways70171 [pathway]   70263 [pathway]   
NDEx NetworkENO1
Atlas of Cancer Signalling NetworkENO1
Wikipedia pathwaysENO1
Orthology - Evolution
OrthoDB2023
GeneTree (enSembl)ENSG00000074800
Phylogenetic Trees/Animal Genes : TreeFamENO1
HOVERGENP06733
HOGENOMP06733
Homologs : HomoloGeneENO1
Homology/Alignments : Family Browser (UCSC)ENO1
Gene fusions - Rearrangements
Fusion Cancer (Beijing)ENO1 [1p36.23]  -  UBE4A [11q23.3]  [FUSC001354]
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerENO1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)ENO1
dbVarENO1
ClinVarENO1
1000_GenomesENO1 
Exome Variant ServerENO1
ExAC (Exome Aggregation Consortium)ENO1 (select the gene name)
Genetic variants : HAPMAP2023
Genomic Variants (DGV)ENO1 [DGVbeta]
DECIPHER (Syndromes)1:8921059-8931635  ENSG00000074800
CONAN: Copy Number AnalysisENO1 
Mutations
ICGC Data PortalENO1 
TCGA Data PortalENO1 
Broad Tumor PortalENO1
OASIS PortalENO1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICENO1  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDENO1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch ENO1
DgiDB (Drug Gene Interaction Database)ENO1
DoCM (Curated mutations)ENO1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)ENO1 (select a term)
intoGenENO1
NCG5 (London)ENO1
Cancer3DENO1(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM172430   
Orphanet
MedgenENO1
Genetic Testing Registry ENO1
NextProtP06733 [Medical]
TSGene2023
GENETestsENO1
Huge Navigator ENO1 [HugePedia]
snp3D : Map Gene to Disease2023
BioCentury BCIQENO1
ClinGenENO1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD2023
Chemical/Pharm GKB GenePA27786
Clinical trialENO1
Miscellaneous
canSAR (ICR)ENO1 (select the gene name)
Probes
Litterature
PubMed192 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineENO1
EVEXENO1
GoPubMedENO1
iHOPENO1
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Apr 12 11:31:14 CEST 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.